Dr. Sarah Premji discusses the FDA approval of giredestrant plus everolimus for ESR1-mutated advanced breast cancer, based on Phase III evERA findings showing improved median progression-free survival from 5.5 to 10 months. She highlights the combination as an additional oral treatment option for patients with hormone receptor-positive disease.
Transcript:
Dr. Premji: As of November 16, 2026, the FDA did approve giredestrant in combination with everolimus based on the Phase 3 evERA study, which showed substantial benefits compared to standard endocrine therapy plus everolimus and ESR1-mutated tumors, which showed an improvement in median PFS from 5.5 months to 10 months in combination.
Giredestrant is an oral SERD with an overall very safe profile, so this is a great option to consider in our patients. This is the second doublet option that we have in our patients with ESR1-mutated tumors hat are hormone-positive advanced breast cancer. Great to have this as an option, and certainly something that we will discuss and consider with our patients.
